Public Equities, L.P.Artal ... Net Worth

The estimated Net Worth of Public Equities, L.P.Artal ... is at least 54.5 百万$ dollars as of 16 December 2020. Public Artal owns over 10,937,500 units of Lexicon Pharmaceuticals Inc stock worth over 54,518,489$ and over the last 4 years Public sold LXRX stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Public Artal LXRX stock SEC Form 4 insiders trading

Public has made over 1 trades of the Lexicon Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Public bought 10,937,500 units of LXRX stock worth 35,000,000$ on 16 December 2020.

The largest trade Public's ever made was buying 10,937,500 units of Lexicon Pharmaceuticals Inc stock on 16 December 2020 worth over 35,000,000$. On average, Public trades about 10,937,500 units every 0 days since 2020. As of 16 December 2020 Public still owns at least 32,259,461 units of Lexicon Pharmaceuticals Inc stock.

You can see the complete history of Public Artal stock trades at the bottom of the page.

Insiders trading at Lexicon Pharmaceuticals Inc

Over the last 18 years, insiders at Lexicon Pharmaceuticals Inc have traded over 161,951$ worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth 731,672,961$ . The most active insiders traders include International S.C.A.Minne P...、International S.C.A.Wittouc...、Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of 5,348,701$. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth 97,252,909$.

What does Lexicon Pharmaceuticals Inc do?

corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio

Complete history of Public Artal stock trades at Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc executives and stock owners

Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Lonnel Coats,
  President, Chief Executive Officer, Director
• Praveen Tyle,
  Executive Vice President - Research and Development
• Jeffrey Wade,
  Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
• Lonnel Coats,
  CEO & Director
• Alan Main,
  Executive Vice President, Commercial Supply Operations
• Jeffrey L. Wade J.D.,
  Pres & CFO
• Dr. Alan J. Main Ph.D.,
  Exec. VP of Innovation & Chemical Sciences
• Dr. Alan J. Main,
  Exec. VP of Innovation & Chemical Sciences
• Brian T. Crum,
  VP, Gen. Counsel & Sec.
• James Tessmer,
  Vice President - Finance and Accounting
• Raymond Debbane,
  Independent Chairman of the Board
• Samuel Barker,
  Independent Director
• Frank Palantoni,
  Independent Director
• Judith Swain,
  Independent Director
• Philippe Amouyal,
  Independent Director
• Robert Lefkowitz,
  Independent Director
• Christopher Sobecki,
  Independent Director
• Alan Nies,
  Independent Director
• Dr. Robert J. Lefkowitz,
  Consultant & Independent Director
• Brian Crum,
  Vice President, General Counsel
• Dr. Craig B. Granowitz M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Kristen L. Alexander,
  VP of Fin. & Accounting
• Chas Schultz,
  Exec. Director of Corp. Communications & Patient Advocacy
• Sam L Barker,
  Director
• Alexander A Santini,
  EVP and CCO
• Pablo Lapuerta,
  EVP and CMO
• International S.C.A.Wittouc...,
  
• Us Partners Llc Ulys, L.L.C...,
  
• Tamar D Howson,
  EVP of Bus Dev
• Barry Mills,
  Director
• Julia P Gregory,
  EVP and CFO
• James R Phd Piggott,
  SVP of Pharm Bio
• Lance K Ishimoto,
  SVP, Intellectual Property
• Clayton Stuart Rose,
  Director
• Public Equities, L.P.Artal ...,
  
• Public Equities, L.P.Artal ...,
  
• International S.C.A.Minne P...,
  
• Diane E. Sullivan,
  Director
• Thomas Garner,
  SVP, Chief Commercial Officer
• Arthur T Sands,
  Pres & CEO
• John Northcott,
  VP, Marketing, Comm Strategy
• Cv Ulys, L.L.C.Debbane Raym...,
  
• International S.C.A.Minne P...,
  
• Brian P Zambrowicz,
  EVP, Chief Scientific Officer
• Llc Invus, L.P.Invus Public...,
  
• International S.C.A.Invus, ...,
  
• Kathleen M Wiltsey,
  Director
• Llc Invus, L.P.Invus Adviso...,
  
• Philip M Brown,
  SVP Clinical Development
• Steven Alan Tragash,
  VP, Corporate Affairs
• Llc Invus, L.P.Invus Adviso...,
  
• Ajay Bansal,
  EVP Corp Dev and CFO
• Kristen Alexander,
  VP, Finance and Accounting
• C.V. Invus,
  Director
• Craig B Granowitz,
  SVP, Chief Medical Officer
• Kenneth B. Kassler Taub,
  SVP, Regulatory & QA
• Wendy Mc Dermott,
  VP, Human Resources
• Kiernan Seth,
  VP, Chief Commercial Officer
• Michael Exton,
  Chief Executive Officer
• Brian Corrigan,
  SVP, Regulatory & QA